European Commission

STRENGTHENING COOPERATION ON HEALTH TECHNOLOGY ASSESSMENT

WHAT IS HTA?

Is this medicine a better treatment for a certain disease?

Will this new scanner really lead to a better diagnosis?

Does this innovative surgery improve the patient's treatment?

HEALTH TECHNOLOGY ASSESSMENT:
procedure for assessing the **added value of new medicines and medical devices**

– PROPOSAL FOR A NEW REGULATION –

WHAT'S NEW?

- **Common** European **assessment methods**
- **Shared data** and expertise
- **Common procedures** across the EU

WHAT ARE THE BENEFITS

- Higher level of **human health protection**
- Faster market access for **innovative products**
- More **transparency** for patients and producers
- No more **duplication** of work for health authorities and industry

AREAS OF HTA COOPERATION

- Joint **clinical assessments**
- Scientific consultations on the development of new products
- Mapping of emerging health technologies
- Voluntary cooperation on other areas (e.g. surgical procedures)

NEW MEDICINES

EU ASSESSMENT
(jointly done by the Member States)

NATIONAL ASSESSMENT

National decisions on pricing and reimbursement

CLINICAL ASSESSMENT
(benefits compared to existing treatments)

NON-CLINICAL ASSESSMENT
(economic, social and ethical aspects)

NEW MEDICAL DEVICES

High-risk devices with high impact on patients, public health and EU health systems

CLINICAL ASSESSMENT
(benefits compared to existing treatments)

NON-CLINICAL ASSESSMENT
(economic, social and ethical aspects)

TIMELINE

31 JANUARY 2018	2019	+3 YEARS	+ 3 YEARS
ADOPTION OF THE **COMMISSION PROPOSAL**	ADOPTION BY **THE PARLIAMENT AND THE COUNCIL**	START OF **APPLICATION OF THE EU REGULATION**	END OF **THE TRANSITIONAL PERIOD** FOR EU MEMBER STATES

https://ec.europa.eu/health/technology_assessment/policy_en

@EU_Health

Health